New Appointments at London Genetics to Drive Strategy Forward
London Genetics Limited announced several appointments to its Board and management team. The new appointments, which include Dr Barrie Ward as Chairman, will drive the next phase of the company’s growth as the importance of pharmacogenetics in drug development increases. They bring important commercial, clinical and academic expertise. In addition to Dr Ward, London Genetics has appointed Dominique Kleyn as CEO and Dr Mark Caulfield as Clinical Director.
Having held senior positions at Glaxo R&D and various biotechnology companies in the US and UK, Dr Ward brings significant industrial and commercial expertise.
Ms Kleyn joins from a series of leadership roles at Imperial College London, where she headed up bioscience Business Development, Technology Transfer and New Venture teams. Prior to this she worked in the biotech sector where she was extensively involved in the exploitation and licensing of intellectual property and development of new businesses.
Clinical Director Dr Mark Caulfield is an expert in the genetics of cardiovascular disease, particularly hypertension. He is Director of the William Harvey Research Institute at Bart’s and the London School of Medicine and Dentistry at Queen Mary, University of London.
Chief Scientific Officer Dr Elizabeth Foot, appointed earlier this year, was in her previous role involved with developing the strategy for and implementation of pharmacogenetics at GlaxoSmithKline and brings significant expertise to the company.
Other news from the department people
